biologic

Idelvion

Coagulation Factor IX (Recombinant), Albumin Fusion Protein

Loss of exclusivityMarch 2028projected — 12-year biologic exclusivity estimate
CompanyCSL Behring Lengnau AG

Drug detail

Brand nameIdelvion
Active ingredientCoagulation Factor IX (Recombinant), Albumin Fusion Protein
Strength1000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2016
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Idelvion patent cliff — loss of exclusivity March 2028 | CliffBio